What is it about?
Diabetes prevalence is growing globally. Sodium-Glucose transporter2 inhibitors (SGLT2Is) are novel class of oral anti-diabetic drugs. This review discuss how SGLT2Is can benefit diabetic individuals via Toll-like receptor(TLR) pathway.
Featured Image
Photo by Mykenzie Johnson on Unsplash
Why is it important?
SGLT2Is are novel class of drugs having unique benefits even for non-diabetic individuals. This publication can guide other researchers toward finding new indications for these drugs based on suggested mechanism of action .
Read the Original
This page is a summary of: Sodium Glucose Transporter-2 Inhibitors (SGLT2Is)-TLRs Axis Modulates Diabetes, Cell Biochemistry and Biophysics, September 2023, Springer Science + Business Media,
DOI: 10.1007/s12013-023-01164-x.
You can read the full text:
Contributors
The following have contributed to this page
